Regulation And Legal
Cipla's InvaGen USFDA Inspection Concludes Zero Observations
Cipla discloses a routine USFDA cGMP inspection at its wholly-owned US subsidiary InvaGen's New York facility.
The inspection was conducted from October 19 to 22, 2026, pursuant to SEBI Listing Regula
